Novo Nordisk and Hims & Hers Reportedly Eyeing Obesity Drug Partnership
Novo Nordisk and Hims & Hers are reportedly exploring a potential partnership to collaborate on the sale of obesity drugs.
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (71/100)Sources
Hims shares shoot up after weight-loss drug deal with Novo Nordisk
US telehealth group and Danish drugmaker have been in dispute over copycat medicines
Read full article →Hims & Hers shares surge 50% after Novo Nordisk drops patent infringement case over compounded weight loss drugs
Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.
Read full article →Hims & Hers stock rockets on reported end to Novo Nordisk weight-loss drug dispute
Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.
By Steve Goldstein
Read full article →Novo Nordisk og onlineapotek begraver stridsøksen med ny aftale i USA
Read full article →Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?
Read full article →Hims & Hers stock jumps on potential pact with Novo Nordisk
Read full article →Hims & Hers Erupts In Epic Squeeze As Novo Nordisk Ends GLP-1 Feud
Hims & Hers Erupts In Epic Squeeze As Novo Nordisk Ends GLP-1 Feud Novo Nordisk confirmed Monday morning that its months-long GLP-1 feud with telehealth firm Hims & Hers Health has, at least for now, been put on ice, with the Danish drugmaker set to sell Wegovy and Ozempic through HIMS' platform by the end of the month. The feud's end was first reported by Bloomberg late Friday and has sparked a panic short squeeze in heavily shorted HIMS shares in New York premarket trading. Bl...
By Tyler Durden
Read full article →
